Zomedica Corp. (NYSE American:ZOM), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced today that Larry Heaton, Chief Executive Officer, will present a company overview at the upcoming virtual H.C. Wainwright BioConnect 2022 Conference, scheduled for January 10-13, 2022.
The presentation will be available on-demand beginning January 10, at 7:00 am ET to registered conference attendees and the public at: https://journey.ct.events/view/67b1dab2-8dd0-4f50-8291-86cf6c38ed3b, and subsequently on the Zomedica website at: https://investors.zomedica.com/events-presentations.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company offering diagnostic and therapeutic products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio of innovative diagnostics and medical devices are designed to improve both patient and practice health. Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
Investor Relations Contacts
PCG Advisory Group
Kirin Smith, President
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1.646.823.8656
| Last Trade: | US$0.07 |
| Daily Change: | -0.0003 -0.41 |
| Daily Volume: | 388,327 |
| Market Cap: | US$70.560M |
October 23, 2025 October 14, 2025 October 09, 2025 September 23, 2025 September 18, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
